Acumen Pharmaceuticals, a US-based drugs company targeting Alzheimer’s disease, has reportedly made a first closing of undisclosed size for its planned $20m series A round from a consortium including medical services provider Praxis Technologies, according to news provider Fierce Biotech.
Also in the A round were venture capital firms BVF Partners (formerly Biotechnology Value Fund), NeuroVentures Fund and Glynn Ventures and private investors.
In 2011, Acumen reacquired ACU-193 and other assets from drugs peer Merck.